Maze Therapeutics, Inc. (MAZE)
Data as of , from SEC Form 4 filings.
See up to 3 months of MAZE. The 7-day demo opens the 1M and 3M ranges and puts MAZE on your watchlist.
Start 7-day demoLatest MAZE insider trades
About Maze Therapeutics, Inc. (MAZE)
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
- SOUTH SAN FRANCISCO, CA
- 141
- 2025
- XNAS
MAZE Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 32 | 227,492 | $6.07M |
| Grant or award | 2 | 72,000 | |
| Option exercise | 20 | 328,848 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
MAZE insider transactions (Form 4)
7975 Form 4 filings on record, the earliest from Aug 17, 2025, newest first. Filing history page 1 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jason V. Coloma - Officer | Open-market sale | Common Stock | 2,593 | $27.02 footnote F2 | $70K | |
| Jason V. Coloma - Officer | Open-market sale | Common Stock | 31,908 | $27.02 footnote F4 | $862K | |
| ||||||
| Harold Bernstein - Officer | Option exercise | Common Stock | 16,141 | $10.42 | $168K | |
| Harold Bernstein - Officer | Open-market sale | Common Stock | 16,141 | $26.93 footnote F2 | $435K | |
| Harold Bernstein - Officer | Option exercise | Stock Option (Right to Buy) | 16,141 | $0.00 | - | |
| ||||||
| Atul Dandekar - Officer | Option exercise | Common Stock | 7,500 | $10.42 | $78K | |
| Atul Dandekar - Officer | Open-market sale | Common Stock | 7,500 | $27.06 footnote F2 | $203K | |
| Atul Dandekar - Officer | Option exercise | Stock Option (Right to Buy) | 7,500 | $0.00 | - | |
| ||||||
| Harold Bernstein - Officer | Open-market sale | Common Stock | 9,705 | $26.22 footnote F2 | $255K | |
| ||||||
| Phillips Courtney - Officer | Open-market sale | Common Stock | 1,738 | $26.38 footnote F2 | $46K | |
| Phillips Courtney - Officer | Open-market sale | Common Stock | 243 | $27.12 footnote F3 | $7K | |
| Phillips Courtney - Officer | Open-market sale | Common Stock | 1,990 | $26.01 footnote F4 | $52K | |
| Phillips Courtney - Officer | Open-market sale | Common Stock | 22 | $25.78 | $567 | |
| ||||||
| Atul Dandekar - Officer | Open-market sale | Common Stock | 2,800 | $26.38 footnote F2 | $74K | |
| Atul Dandekar - Officer | Open-market sale | Common Stock | 391 | $27.12 footnote F3 | $11K | |
| Atul Dandekar - Officer | Open-market sale | Common Stock | 3,207 | $26.01 footnote F4 | $83K | |
| Atul Dandekar - Officer | Open-market sale | Common Stock | 36 | $25.81 | $929 | |
| ||||||
| Jason V. Coloma - Officer | Open-market sale | Common Stock | 9,852 | $26.38 footnote F2 | $260K | |
| Jason V. Coloma - Officer | Open-market sale | Common Stock | 1,375 | $27.12 footnote F3 | $37K | |
| Jason V. Coloma - Officer | Open-market sale | Common Stock | 11,282 | $26.01 footnote F4 | $293K | |
| Jason V. Coloma - Officer | Open-market sale | Common Stock | 129 | $25.77 | $3K | |
| ||||||
| Harold Bernstein - Officer | Open-market sale | Common Stock | 4,481 | $26.38 footnote F2 | $118K | |
| Harold Bernstein - Officer | Open-market sale | Common Stock | 625 | $27.12 footnote F3 | $17K | |
| Harold Bernstein - Officer | Open-market sale | Common Stock | 5,130 | $26.01 footnote F4 | $133K | |
| Harold Bernstein - Officer | Open-market sale | Common Stock | 59 | $25.78 | $2K | |
| ||||||
| Phillips Courtney - Officer | Option exercise | Common Stock | 11,000 | $0.00 | - | |
| Phillips Courtney - Officer | Option exercise | Restricted Stock Units | 11,000 | $0.00 | - | |
| Atul Dandekar - Officer | Option exercise | Common Stock | 12,500 | $0.00 | - | |
| Atul Dandekar - Officer | Option exercise | Restricted Stock Units | 12,500 | $0.00 | - | |
| Jason V. Coloma - Officer | Open-market sale | Common Stock | 2,593 | $26.31 footnote F2 | $68K | |
| Jason V. Coloma - Officer | Open-market sale | Common Stock | 31,908 | $26.29 footnote F4 | $839K | |
| Jason V. Coloma - Officer | Option exercise | Common Stock | 50,000 | $0.00 | - | |
| Jason V. Coloma - Officer | Option exercise | Restricted Stock Units | 50,000 | $0.00 | - | |
| ||||||
| Harold Bernstein - Officer | Option exercise | Common Stock | 20,000 | $0.00 | - | |
| Harold Bernstein - Officer | Option exercise | Common Stock | 16,141 | $10.42 | $168K | |
| Harold Bernstein - Officer | Open-market sale | Common Stock | 16,141 | $26.36 footnote F2 | $426K | |
| Harold Bernstein - Officer | Option exercise | Stock Option (Right to Buy) | 16,141 | $0.00 | - | |
| Harold Bernstein - Officer | Option exercise | Restricted Stock Units | 20,000 | $0.00 | - | |
| ||||||
| Atul Dandekar - Officer | Option exercise | Common Stock | 7,500 | $10.42 | $78K | |
| Atul Dandekar - Officer | Open-market sale | Common Stock | 7,500 | $27.58 footnote F2 | $207K | |
| Atul Dandekar - Officer | Option exercise | Stock Option (Right to Buy) | 7,500 | $0.00 | - | |
| ||||||
| Sophie Kornowski - Director | Grant or award | Stock Option (Right to Buy) | 36,000 | $0.00 | - | |
 Paula A. Johnson - Director | Grant or award | Stock Option (Right to Buy) | 36,000 | $0.00 | - | |
| Harold Bernstein - Officer | Option exercise | Common Stock | 16,142 | $10.42 | $168K | |
| Harold Bernstein - Officer | Open-market sale | Common Stock | 16,142 | $27.61 footnote F2 | $446K | |
| Harold Bernstein - Officer | Option exercise | Stock Option (Right to Buy) | 16,142 | $0.00 | - | |
| ||||||
| Jason V. Coloma - Officer | Open-market sale | Common Stock | 2,439 | $26.71 footnote F2 | $65K | |
| Jason V. Coloma - Officer | Open-market sale | Common Stock | 154 | $27.09 footnote F4 | $4K | |
| Jason V. Coloma - Officer | Open-market sale | Common Stock | 30,304 | $26.71 footnote F5 | $810K | |
| Jason V. Coloma - Officer | Open-market sale | Common Stock | 1,604 | $27.09 footnote F7 | $43K | |
| ||||||
| Atul Dandekar - Officer | Option exercise | Common Stock | 7,500 | $10.42 | $78K | |
| Atul Dandekar - Officer | Open-market sale | Common Stock | 7,100 | $27.31 footnote F2 | $194K | |
| Atul Dandekar - Officer | Open-market sale | Common Stock | 400 | $27.89 footnote F3 | $11K | |
| Atul Dandekar - Officer | Option exercise | Stock Option (Right to Buy) | 7,500 | $0.00 | - | |
| ||||||
| Harold Bernstein - Officer | Open-market sale | Common Stock | 1,200 | $30.34 footnote F3 | $36K | |
| Harold Bernstein - Officer | Option exercise | Stock Option (Right to Buy) | 14,609 | $0.00 | - | |
| Harold Bernstein - Officer | Option exercise | Common Stock | 14,609 | $10.42 | $152K | |
| Harold Bernstein - Officer | Open-market sale | Common Stock | 13,409 | $29.87 footnote F2 | $400K | |
| ||||||
| Jason V. Coloma - Officer | Open-market sale | Common Stock | 2,593 | $29.98 footnote F2 | $78K | |
| Jason V. Coloma - Officer | Open-market sale | Common Stock | 30,311 | $29.95 footnote F4 | $908K | |
| Jason V. Coloma - Officer | Open-market sale | Common Stock | 1,597 | $30.44 footnote F6 | $49K | |
| ||||||
| Atul Dandekar - Officer | Option exercise | Common Stock | 7,500 | $10.42 | $78K | |
| Atul Dandekar - Officer | Open-market sale | Common Stock | 7,500 | $28.02 | $210K | |
| Atul Dandekar - Officer | Option exercise | Stock Option (Right to Buy) | 7,500 | $0.00 | - | |
| Jason V. Coloma - Officer | Open-market sale | Common Stock | 2,040 | $26.00 | $53K | |
| Jason V. Coloma - Officer | Open-market sale | Common Stock | 23,865 | $26.05 footnote F5 | $622K | |
| Jason V. Coloma - Officer | Open-market sale | Common Stock | 1,953 | $26.00 footnote F2 | $51K | |
| ||||||
| Daniel K. Spiegelman | Grant or award | Stock Option (Right to Buy) | 18,000 | $0.00 | - | |
| Richard H. Scheller | Grant or award | Stock Option (Right to Buy) | 18,000 | $0.00 | - | |
 Jonathan E. Lim | Grant or award | Stock Option (Right to Buy) | 18,000 | $0.00 | - | |
| Herve Hoppenot | Grant or award | Stock Option (Right to Buy) | 18,000 | $0.00 | - | |
| Charles J. Homcy | Grant or award | Stock Option (Right to Buy) | 18,000 | $0.00 | - | |
| Nancy C. Andrews | Grant or award | Stock Option (Right to Buy) | 18,000 | $0.00 | - | |
| Jason V. Coloma - Officer | Open-market sale | Common Stock | 6,090 | $26.20 footnote F2 | $160K | |
| Jason V. Coloma - Officer | Open-market sale | Common Stock | 553 | $26.24 footnote F4 | $15K | |
| ||||||
| Harold Bernstein - Officer | Option exercise | Common Stock | 14,853 | $10.42 | $155K | |
| Harold Bernstein - Officer | Open-market sale | Common Stock | 13,253 | $25.57 footnote F2 | $339K | |
| Harold Bernstein - Officer | Open-market sale | Common Stock | 1,600 | $26.36 footnote F3 | $42K | |
| Harold Bernstein - Officer | Option exercise | Stock Option (Right to Buy) | 14,853 | $0.00 | - | |
| ||||||
Item 5.02, 7.01, 9.01
Item 2.02, 9.01
Item 5.07
Item 5.02
Recent MAZE Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| HAROLD BERNSTEIN | Officer | 16,141 | $439K | View on EDGAR | |
| Coloma Jason V | Officer | 34,501 |
MAZE insider trading FAQ
What is the latest insider trade for MAZE?
Maze Therapeutics, Inc. (MAZE) had 18 insider filings in the last 90 days, with the most recent on 2026-10-02. The full record for MAZE runs to 75 Form 4 filings, the earliest from 2025-08-17. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying MAZE stock?
No insider purchases of MAZE were filed in the last 90 days.
How many insiders are selling MAZE stock?
32 insider sales of MAZE were filed in the last 90 days, totaling $6.07M.
Where can I see MAZE SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects MAZE Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Jason V. Coloma view on EDGAR
- - Harold Bernstein view on EDGAR
- - Atul Dandekar view on EDGAR
- - Harold Bernstein view on EDGAR
- - Phillips Courtney view on EDGAR
- - Atul Dandekar view on EDGAR
- - Jason V. Coloma view on EDGAR
- - Harold Bernstein view on EDGAR
- - Phillips Courtney view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where MAZE's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow MAZE with a 7-day demo
- MAZE on your watchlist
- Every MAZE Form 4 filing on record
- Up to 3 months of MAZE price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
